S M Edgerton

2.0k total citations · 1 hit paper
14 papers, 1.7k citations indexed

About

S M Edgerton is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, S M Edgerton has authored 14 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Cancer Research. Recurrent topics in S M Edgerton's work include Cancer-related Molecular Pathways (4 papers), HER2/EGFR in Cancer Research (3 papers) and Cancer, Lipids, and Metabolism (3 papers). S M Edgerton is often cited by papers focused on Cancer-related Molecular Pathways (4 papers), HER2/EGFR in Cancer Research (3 papers) and Cancer, Lipids, and Metabolism (3 papers). S M Edgerton collaborates with scholars based in United States. S M Edgerton's co-authors include Ann D. Thor, Dan H. Moore, Helene S. Smith, Brian H. Mayall, Joseph Marcus, L. Schwartz, Ernest S. Kawasaki, Henry T. Lynch, Jolanta Kupryjańczyk and Roberta L. Beauchamp and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JNCI Journal of the National Cancer Institute and Oncogene.

In The Last Decade

S M Edgerton

14 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Accumulation of p53 Tumor Suppressor Gene Protein: An Independent Marker of Prognosis in Breast Cancers

1992 638 citations Ann D. Thor, Dan H. Moore et al. JNCI Journal of the National Cancer Institute profile →

Peers

Countries citing papers authored by S M Edgerton

Since Specialization

Citations

This map shows the geographic impact of S M Edgerton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S M Edgerton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S M Edgerton more than expected).

Fields of papers citing papers by S M Edgerton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S M Edgerton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S M Edgerton. The network helps show where S M Edgerton may publish in the future.

Co-authorship network of co-authors of S M Edgerton

This figure shows the co-authorship network connecting the top 25 collaborators of S M Edgerton. A scholar is included among the top collaborators of S M Edgerton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S M Edgerton. S M Edgerton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer 2018 ·PubMed ·Reema S. Wahdan-Alaswad, S M Edgerton, Hilmi S. Salem, Ann D. Thor	41
2	Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation 2010 ·Carcinogenesis ·Xiao Yang, Shi‐Yi Yang, (unknown), Bolin Liu, S M Edgerton, (unknown), L. T. Archer, Ann D. Thor	27
3	Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells 2010 ·Oncogene ·Partha Das, Ann D. Thor, S M Edgerton, Sayka Barry, (unknown), Frank E. Jones	36
4	erbB-2 (HER-2) and Breast Cancer Progression 2003 ·Applied immunohistochemistry & molecular morphology ·S M Edgerton, (unknown), Douglas E. Merkel, Ann D. Thor	76
5	Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. 2001 ·PubMed ·(unknown), S M Edgerton, Dan H. Moore, Ann D. Thor	101
6	Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. 2001 ·PubMed ·Ann D. Thor, S M Edgerton, (unknown), Dan H. Moore, D J Kwiatkowski	68
7	Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. 1997 ·PubMed ·S Krajewski, Ann D. Thor, S M Edgerton, David H. Moore, (unknown), John C. Reed	64
8	Tumor Angiogenesis as a Prognostic Assay for Invasive Ductal Breast Carcinoma 1995 ·JNCI Journal of the National Cancer Institute ·Kristian F. Axelsson, Britt‐Marie Ljung, Dan H. Moore, Ann D. Thor, Karen Chew, S M Edgerton, Helene S. Smith, Brian H. Mayall	188
9	Response 1995 ·JNCI Journal of the National Cancer Institute ·(unknown), (unknown), Karen Chew, Brian H. Mayall, Dan H. Moore, (unknown), Ann D. Thor, S M Edgerton	1
10	Prognostic value of Cathepsin D expression in breast cancer: Immunohistochemical assessment and correlation with radiometric assay 1994 ·Annals of Oncology ·(unknown), Christopher C. Benz, Charles M Dollbaum, Dan H. Moore, S M Edgerton, David T. Zava, Ann D. Thor	22
11	p53 gene mutations and protein accumulation in human ovarian cancer. 1993 ·Proceedings of the National Academy of Sciences ·Jolanta Kupryjańczyk, Ann D. Thor, Roberta L. Beauchamp, Victoria C. Merritt, S M Edgerton, Douglas A. Bell, David W. Yandell	255
12	Accumulation of p53 Tumor Suppressor Gene Protein: An Independent Marker of Prognosis in Breast Cancers breakdown → 1992 ·JNCI Journal of the National Cancer Institute ·Ann D. Thor, Dan H. Moore, S M Edgerton, Ernest S. Kawasaki, (unknown), Henry T. Lynch, Joseph Marcus, L. Schwartz, (unknown), Brian H. Mayall, Helene S. Smith	638
13	pS2 expression and response to hormonal therapy in patients with advanced breast cancer. 1991 ·PubMed ·Lawrence H. Schwartz, Frederick C. Koerner, S M Edgerton, Joanna Sawicka, Marc Rio, Jean‐Pierre Bellocq, Pierre Chambon, Ann D. Thor	107
14	Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. 1989 ·PubMed ·Ann D. Thor, Laurent H. Schwartz, Frederick C. Koerner, S M Edgerton, Steven J. Skates, (unknown), (unknown), Dennis Panicali, (unknown), Howard Fingert	104

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact